%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-07-17T11:25:18-04:00
2017-07-17T11:25:20-04:00
2017-07-17T11:25:20-04:00
Adobe InDesign CC 2017 (Windows)
uuid:7a60ba66-49b5-4e70-b159-8f3a23044a85
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:13b4bd4d-9d34-a74d-be3e-c242f9d65809
proof:pdf
xmp.iid:18711069-68a0-ad4d-a309-d37d6200ae74
xmp.did:231fb3c9-c64f-f94d-bfbe-30adec2435d3
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-07-17T11:25:18-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
45 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 175.3037 263.918 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Risk strati\037cation tools for pulmonary)-9.9 ( )]TJ
0 -1.2 TD
(embolism \(PE\):)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc T*
(a. do not exist.)Tj
T*
(b. have no role in the management of PE.)Tj
T*
(c. have high negative predictive value for )Tj
T*
(mortality in low-risk PE.)Tj
T*
(d. have high positive predictive value for )Tj
T*
(mortality in high-risk PE.)Tj
T*
(e. None of the above)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc -1.588 -1.729 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In the ICU, resilient family members)-10 ( )]TJ
0.01 Tw T*
(experience:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 Tw T*
(a. fewer symptoms of depression.)Tj
T*
[(b. fewer symptoms of anxiety)92 (.)]TJ
T*
(c. fewer symptoms of acute stress.)Tj
T*
(d. more satisfaction with the care )Tj
T*
(provided.)Tj
T*
(e. All of the above)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 20.082 19.729 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The use of dexmedetomidine in patients)-10 ( )]TJ
T*
(with sepsis:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc T*
[(a. did not result in reduced ventilator)55 (-free )]TJ
T*
(days.)Tj
T*
(b. was associated with a reduction in 28-)Tj
T*
[(day mortality)92 (.)]TJ
T*
(c. resulted in overall poor levels of )Tj
T*
(sedation.)Tj
T*
(d. was associated with increased rates of )Tj
T*
[(hemodynamic instability)92 (.)]TJ
T*
(e. Both b and d)Tj
-0.03 Tc 10 0 0 10 163.3276 733.8799 Tm
[(non-GABA pathways, it is thought to be)-29.9 ( )]TJ
T*
[(less delirium-inducing and generate a more)-30 ( )]TJ
T*
(natural sleep cycle.)Tj
0.03 Tw 5.83 0 0 5.83 238.9966 713.21 Tm
(2,3)Tj
0 Tw 10 0 0 10 246.5756 709.8799 Tm
[( It is observed to have)-30 ( )]TJ
-8.325 -1.2 Td
[(anti-in\036ammatory properties by promoting)-30 ( )]TJ
T*
[(macrophage phagocytosis and bactericidal)-30 ( )]TJ
T*
[(killing and reducing levels of TNF-alpha,)-30 ( )]TJ
T*
(IL-1beta, and IL-6 in patients with sepsis.)Tj
0 Tc 5.83 0 0 5.83 329.8859 665.21 Tm
(4)Tj
-0.03 Tc 10 0 0 10 332.9525 661.8799 Tm
[( It)-30 ( )]TJ
-16.962 -1.2 Td
[(also can attenuate sympathetic hyperdynamic)-30 ( )]TJ
T*
[(responses, which theoretically can translate)-29.9 ( )]TJ
T*
(to myocardial protection.)Tj
0 Tc 5.83 0 0 5.83 265.8366 629.21 Tm
(5)Tj
-0.03 Tc 10 0 0 10 268.9032 625.8799 Tm
[( Whether these)-30 ( )]TJ
-10.558 -1.2 Td
(physiologic observations translate to signi\037)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(cant clinical outcomes has been the subject of)-30 ( )]TJ
T*
[(interest in recent studies. In patients requiring)-30 ( )]TJ
T*
[(sedation for invasive mechanical ventilation)-30 ( )]TJ
T*
[(in general, dexmedetomidine is associated)-29.9 ( )]TJ
T*
[(with less delirium and a shorter time on the)-30 ( )]TJ
T*
[(ventilator when compared with midazolam)-30 ( )]TJ
T*
(but not propofol.)Tj
0.03 Tw 5.83 0 0 5.83 233.2673 533.21 Tm
(6,7)Tj
0 Tw 10 0 0 10 240.8463 529.8799 Tm
( Patients receiving dexme)Tj
0 Tc (-)Tj
-0.03 Tc -7.752 -1.2 Td
[(detomidine had enhanced arousability and)-30 ( )]TJ
T*
[(ability to communicate pain, which may have)-30 ( )]TJ
T*
(contributed to earlier mobilization, extuba)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(tion, and recovery)92 (. No signi\037cant differences)-29.9 ( )]TJ
T*
[(were observed in ICU or hospital lengths of)-30 ( )]TJ
T*
(stay or mortality in these randomized trials.)Tj
0.03 Tw 5.83 0 0 5.83 338.7258 461.2099 Tm
(6,7)Tj
0 Tc 0 Tw 10 0 0 10 346.4796 457.8799 Tm
( )Tj
-0.03 Tc -18.315 -1.2 Td
[(In contrast, a previous subgroup analysis of)-30 ( )]TJ
T*
[(the Maximizing Ef\037cacy of T)86.1 (argeted Seda)]TJ
0 Tc (-)Tj
-0.03 Tc T*
[(tion and Reducing Neurological Dysfunction)-30 ( )]TJ
T*
[(trial found that use of dexmedetomidine was)-30 ( )]TJ
T*
[(associated with lower 28-day mortality \(16%)-30 ( )]TJ
T*
(vs. 41%; HR, 0.3; 95% CI, 0.1-0.9; )Tj
/T1_2 1 Tf
0 Tc (P)Tj
/T1_1 1 Tf
-0.03 Tc 15.371 0 Td
[( = 0.03\))-30 ( )]TJ
-15.371 -1.2 Td
[(compared to midazolam, but only in patients)-30 ( )]TJ
T*
(with sepsis.)Tj
0 Tc 5.83 0 0 5.83 209.1871 365.2099 Tm
(1)Tj
-0.03 Tc 10 0 0 10 212.2537 361.8799 Tm
[( However)111 (, caution should be used)-30 ( )]TJ
-4.893 -1.2 Td
[(in interpreting these \037ndings, as this was a)-30 ( )]TJ
T*
[(subgroup analysis of a larger study and, as)-29.9 ( )]TJ
T*
[(such, had small numbers, was not powered to)-30 ( )]TJ
T*
[(examine speci\037c outcomes, and was subject to)-30 ( )]TJ
20.296 42 Td
(serious confounding given its lack of ran)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(domization. Indeed, results of the currently)-30 ( )]TJ
T*
[(reported randomized trial have not supported)-30 ( )]TJ
T*
[(a clear bene\037t regarding mortality with the use)-29.9 ( )]TJ
T*
[(of dexmedetomidine. Whether these results are)-30 ( )]TJ
T*
[(related to lack of power)111 (, heterogeneity of the)-29.9 ( )]TJ
T*
[(comparison group \(the control group could)-30 ( )]TJ
T*
[(receive either propofol or a benzodiazepine\),)-30 ( )]TJ
T*
[(or other reasons is unclear and remains to be)-30 ( )]TJ
T*
(addressed based on future studies. )Tj
/C2_0 1 Tf
0 Tc 14.232 0 Td
<0084>Tj
/TT0 1 Tf
0.01 Tc -0.01 Tw 9.25 0 0 9.25 366.2845 600.48 Tm
(REFERENCES)Tj
/TT1 1 Tf
-0.03 Tc 0 Tw 0 -1.189 TD
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(P)54.7 (andharipande PP)239.8 (, et al. Effect of dexmedetomidine)-30 ( )]TJ
T*
[(versus lorazepam on outcome in patients with)-29.8 ( )]TJ
T*
[(sepsis: An a priori-designed analysis of the MENDS)-30 ( )]TJ
T*
(randomized controlled trial. )Tj
/TT2 1 Tf
(Crit Care)Tj
/TT1 1 Tf
( 2010;14:R38.)Tj
-1.946 -1.189 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(P)54.7 (andharipande PP)239.8 (, et al. Effect of sedation with)-29.9 ( )]TJ
T*
[(dexmedetomidine vs lorazepam on acute brain)-29.9 ( )]TJ
0 -1.189 TD
[(dysfunction in mechanically ventilated patients:)-30 ( )]TJ
0 -1.189 TD
(The MENDS randomized controlled trial. )Tj
/TT2 1 Tf
0.03 Tw (JAMA)Tj
/TT1 1 Tf
0 Tc 0 Tw 16.918 0 Td
( )Tj
-0.03 Tc 0.03 Tw -16.918 -1.189 Td
(2007;298:2644-2653.)Tj
0 Tw -1.946 -1.189 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Nelson LE, et al. The alpha2-adrenoceptor agonist)-30.1 ( )]TJ
0 -1.189 TD
[(dexmedetomidine converges on an endogenous)-30.1 ( )]TJ
0 -1.189 TD
(sleep-promoting pathway to exert its sedative ef)Tj
0 Tc (-)Tj
-0.03 Tc 0.03 Tw T*
(fects. )Tj
/TT2 1 Tf
1.991 0 Td
(Anesthesiology)Tj
/TT1 1 Tf
0 Tw ( 2003;98:428-436.)Tj
-3.937 -1.189 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(MacL)17.4 (aren R. Immunosedation: A consideration for)-30 ( )]TJ
0.03 Tw T*
(sepsis. )Tj
/TT2 1 Tf
0 Tw 2.453 0 Td
(Crit Care)Tj
/TT1 1 Tf
( 2009;13:191.)Tj
-4.399 -1.189 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Zamani MM, et al. Survival benefits of dexmedeto)Tj
0 Tc 17.587 0 Td
(-)Tj
-0.03 Tc -17.587 -1.189 Td
(midine used for sedating septic patients in inten)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(sive care setting: A systematic review)72.9 (. )]TJ
/TT2 1 Tf
(J Crit Care)Tj
/TT1 1 Tf
0 Tc 16.806 0 Td
( )Tj
-0.025 Tc 0.025 Tw -16.806 -1.189 Td
(2016;32:93-100.)Tj
0 Tw -1.946 -1.189 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Riker RR, et al. for the SEDCOM \(Safety and)-25.2 ( )]TJ
T*
(Efficacy of Dexmedetomidine Compared with Mid)Tj
0 Tc (-)Tj
-0.025 Tc T*
(azolam\) Study Group. )Tj
/TT2 1 Tf
0.025 Tw (JAMA)Tj
/TT1 1 Tf
0 Tw ( 2009;301:489-499.)Tj
-1.946 -1.189 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Jakob SM, et al. Dexmedetomidine vs midazolam)-25 ( )]TJ
-0.001 Tw T*
(or propofol for sedation during prolonged mechani)Tj
0 Tc 0 Tw (-)Tj
-0.025 Tc T*
[(cal ventilation: T)155.7 (wo randomized controlled trials.)-24.9 ( )]TJ
/TT2 1 Tf
0.025 Tw T*
(JAMA)Tj
/TT1 1 Tf
0 Tw ( 2012;307:1151-1160.)Tj
ET
endstream
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 85.68 120.33 670.32 re
f
18 27 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 24.66 70.6548 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 TD
[(company)-55.8 (\222s site? There are numerous opportunities for you )]TJ
0 -1.143 TD
(to leverage editorial recognition for the benefit of your )Tj
0 -1.143 TD
[(brand. Call us at \(800\) 688-2421 or email us at R)19.8 (eprints@)]TJ
T*
(AHCMedia.com.)Tj
25.825 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
T*
(copies, site-licenses, or electronic distribution. For pricing )Tj
0 -1.143 TD
(information, please contact our Group Account Managers )Tj
0 -1.143 TD
(at Groups@AHCMedia.com or \(866\) 213-0844.)Tj
25.825 3.429 Td
[(T)175 (o reproduce any part of AHC newsletters for educational )]TJ
T*
(purposes, please contact The Copyright Clearance Center )Tj
0 -1.143 TD
(for permission at info@copyright.com or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
0.25 w
163.391 89.285 392.225 189.23 re
S
/CS0 cs 1 scn
163.328 277.32 392.414 17.367 re
f
BT
0 0 0 0 k
12 0 0 12 304.0168 281.4156 Tm
(CME/CE QUESTIONS)Tj
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 6.5 0 0 6.5 23.265 745.2292 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.231 TD
[(Betty T)175 (ran, MD, MSc)]TJ
/TT1 1 Tf
T*
[(Assistant P)35.7 (rofessor of Medicine)]TJ
T*
[(P)35.7 (ulmonary and Critical Care Medicine)]TJ
T*
[(R)17.5 (ush University Medical Center)]TJ
0.01 Tw T*
(Chicago)Tj
/T1_0 1 Tf
0 Tw 0 -2.462 TD
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.231 TD
(William Thompson)Tj
/TT1 1 Tf
0.01 Tw (, )Tj
/TT0 1 Tf
6 0 0 6 74.9265 681.2292 Tm
(MD)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 23.265 673.2292 Tm
[(Associate P)35.7 (rofessor of Medicine)]TJ
0 Tc T*
[(University of W)54.7 (ashington, Seattle)]TJ
/T1_0 1 Tf
-0.01 Tc 6 0 0 6 23.265 649.2292 Tm
(NURSE PLANNER)Tj
/TT0 1 Tf
6.5 0 0 6.5 23.265 641.2292 Tm
[(Jane Guttendorf)35.5 (, DNP)239.7 (, RN, CRNP)239.7 (,)-9.9 ( )]TJ
T*
[(A)17.5 (CNPBC, CCRN)]TJ
/TT1 1 Tf
6 0 0 6 23.265 625.7292 Tm
[(Assistant P)35.7 (rofessor)100.5 (, Acute & T)174.7 (ertiary Care,)]TJ
0 -1.333 TD
[(University of P)17.6 (ittsburgh, School of Nursing)]TJ
/T1_0 1 Tf
6.5 0 0 6.5 23.265 599.7275 Tm
[(EDITORIAL ADVISOR)92 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.231 TD
[(K)17.8 (ay Ball, PhD, RN, CNOR, F)35.7 (AAN)]TJ
/TT1 1 Tf
T*
[(P)35.7 (rofessor of Nursing, Otterbein University)87 (,)-9.9 ( )]TJ
T*
[(W)54.9 (esterville, OH)]TJ
/TT0 1 Tf
0 -2.462 TD
(Elaine Chen, MD)Tj
/TT1 1 Tf
0 -1.231 TD
[(Assistant P)35.7 (rofessor)100.5 (, Department of Internal)-10.2 ( )]TJ
0 -1.231 TD
[(Medicine, Division of P)35.7 (ulmonary and Critical)-10.2 ( )]TJ
0 -1.231 TD
[(Care Medicine, Section of P)54.8 (alliative Medicine,)-10 ( )]TJ
T*
[(R)17.5 (ush University Medical Center)100.5 (,)]TJ
0.01 Tw T*
(Chicago)Tj
/TT0 1 Tf
0 Tw 0 -2.462 TD
[(Richard H)17.7 (. K)17.7 (allet, MS, RRT)156 (, F)35.7 (AARC,)-10 ( )]TJ
0.01 Tw 0 -1.231 TD
(FCCM)Tj
/TT1 1 Tf
0 Tw 0 -1.231 TD
(Director of Quality Assurance)Tj
0 -1.231 TD
[(R)17.5 (espiratory Care Services)]TJ
T*
(Department of Anesthesia)Tj
T*
[(San F)54.9 (rancisco General Hospital)]TJ
/TT0 1 Tf
0 -2.462 TD
[(James E. McFeely)87.1 (, MD)]TJ
/TT1 1 Tf
0 -1.231 TD
[(Medical Director)100.5 (, Critical Care Units, Alta)-10.1 ( )]TJ
T*
[(Bates Summit Medical Center)100.6 (, Berkeley)87 (, CA)]TJ
/TT0 1 Tf
0 -2.462 TD
[(Samuel Nadler)100.6 (, MD, PhD)]TJ
/TT1 1 Tf
0 -1.231 TD
[(Critical Care, P)35.7 (ulmonary Medicine)]TJ
T*
[(The P)54.7 (olyclinic Madison Center)100.6 (, Seattle)]TJ
T*
(Clinical Instructor)Tj
0 -1.231 TD
[(University of W)54.9 (ashington, Seattle)]TJ
/TT0 1 Tf
0 -2.462 TD
(Alexander Niven, MD)Tj
/TT1 1 Tf
0 -1.231 TD
(Senior Associate Consultant)Tj
T*
[(Division of P)35.7 (ulmonary/Critical Care Medicine)]TJ
T*
(Mayo Clinic)Tj
0 Tc 4.4 0 Td
( )Tj
-0.01 Tc -4.4 -1.231 Td
[(R)17.5 (ochester)100.6 (, MN)]TJ
/TT0 1 Tf
0 -2.462 TD
[(K)17.8 (athryn R)17.6 (adigan, MD, MSc)]TJ
/TT1 1 Tf
0 -1.231 TD
[(Attending Physician, Division of P)35.7 (ulmonary)-9.9 ( )]TJ
T*
(and Critical Care)Tj
T*
[(Stroger Hospital of Cook County)87.1 (,)]TJ
0.01 Tw T*
(Chicago)Tj
/TT0 1 Tf
0 Tw 0 -2.462 TD
[(T)175 (rushil Shah, MD, MS)]TJ
/TT1 1 Tf
0 -1.231 TD
[(Assistant P)35.7 (rofessor of Medicine)]TJ
T*
[(University of T)174.8 (exas Southwestern)]TJ
/TT0 1 Tf
0 -2.462 TD
[(Eric C. W)54.5 (alter)100.6 (, MD, MSc)]TJ
/TT1 1 Tf
0 -1.231 TD
[(P)35.7 (ulmonary and Critical Care Medicine)]TJ
-0.004 Tw 0 -1.231 TD
[(Northwest P)54.8 (ermanente and K)17.6 (aiser Sunnyside)-10 ( )]TJ
0 Tw 0 -1.231 TD
(Medical Center)Tj
T*
[(P)54.7 (ortland, OR)]TJ
/T1_0 1 Tf
0 -2.462 TD
(EDITOR EMERITUS)Tj
/TT0 1 Tf
0 -1.231 TD
(David J. Pierson, MD)Tj
/TT1 1 Tf
T*
[(P)35.7 (rofessor Emeritus)-10.2 ( )]TJ
0 Tc 7.226 0 Td
( )Tj
-0.01 Tc -7.226 -1.231 Td
[(P)35.7 (ulmonary and Critical Care Medicine)-10.1 ( )]TJ
T*
[(University of W)54.9 (ashington, Seattle)]TJ
/T1_0 1 Tf
0.01 Tw 6 0 0 6 23.265 143.7276 Tm
(EDITOR)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 23.265 135.7276 Tm
(Jonathan Springston)Tj
/T1_0 1 Tf
6 0 0 6 23.265 120.2276 Tm
(EXECUTIVE EDITOR)Tj
/TT1 1 Tf
6.5 0 0 6.5 23.265 112.2276 Tm
[(L)17.4 (eslie Coplin)]TJ
/T1_0 1 Tf
6 0 0 6 23.265 97.2276 Tm
[(SENIOR ACCREDIT)74 (A)74 (TIONS OFFICER)]TJ
/TT1 1 Tf
0 -1.25 TD
[(L)17.4 (ee L)17.4 (andenberger)]TJ
ET
endstream
endobj
47 0 obj
<>
endobj
48 0 obj
<>
endobj
49 0 obj
<>
endobj
54 0 obj
<>
endobj
55 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
56 0 obj
<>stream
HtVXU~p:IE1貈\PA@1^2E͌U!WɐU#U4EIi[w\Tvٞ9p0&SeVQ`/ |F2̓BVl49މ>ŀLb~YA^VnS~PlB9S1zU<(Oʩ37'e PUagB{g98s(W]4--6i^i÷H&gG"\WVZʅ#3*8N%ANo~ e1'y03}Rs`vU8M$OI+oyAdE?G'gWKF
а!1Æǎ7/%8f+IOI&ON2J>}k33g/(5{NQ\SɼҲ*^ƢK.{soUZfYznyo5lpwU[[O7C6}voG~Oԗ|u\+W]q;wu@ h ae2S *b;'4AMVt$]^ǜj!v091^b),bQu{;c9=6baZ?$i͠ekւ[-Vޛ>˦[rw&p`8Sc:Wfvi @4}
1lx`->^QrlB`*4.k=C7v|h@6r8۲ŻBcF;HAHG(E+:ayۻ#/abM_W$1Jr|v3O"Jo9`X5.Fc (G &G8Яvw-ɂ*{Mtuqvr)5ʶVƵm֝QVInaZ;-]9y`sm,n` cylegur %ZF>o.Kt{dtκ赉XQ@/Ə.Pnj}ٮ5~pȁ`R/
(ysK:UmP>RŪb gV>2QQ*OPɠRF
VIР^^jUPa:3(HWyQ
%ٓPvO6m,0t:ՃMSOpr"9K
[yWx:yItE7-xDQ]=qI?:褯H;up>FŇ3&